17 results on '"Grünhagen, Dirk"'
Search Results
2. Assessing patients’ needs in the follow-up after treatment for colorectal cancer—a mixed-method study
- Author
-
Voigt, Kelly R., de Bruijn, Esmee A., Wullaert, Lissa, Witteveen, Léon, Verhoef, Cornelis, Husson, Olga, and Grünhagen, Dirk J.
- Published
- 2024
- Full Text
- View/download PDF
3. The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases
- Author
-
Höppener, Diederik J., Stook, Jean-Luc P. L., Galjart, Boris, Nierop, Pieter M. H., Nagtegaal, Iris D., Vermeulen, Peter B., Grünhagen, Dirk J., Verhoef, Cornelis, and Doukas, Michail
- Published
- 2022
- Full Text
- View/download PDF
4. Feasibility, reliability and satisfaction of (automated) capillary carcinoembryonic antigen measurements for future home‐based blood sampling: the prospective CASA‐I study.
- Author
-
Voigt, Kelly R., Wullaert, Lissa, Gobardhan, P. D., Doornebosch, P. G., Verhoef, Cornelis, Husson, Olga, Ramakers, Christian, and Grünhagen, Dirk J.
- Subjects
PEARSON correlation (Statistics) ,BLOOD collection ,BLOOD sampling ,COLORECTAL cancer ,SATISFACTION ,PAIN measurement ,CARCINOEMBRYONIC antigen - Abstract
Aim: Follow‐up for colorectal cancer (CRC) necessitates regular monitoring of carcinoembryonic antigen (CEA) at the hospital. Capillary home‐based blood collection, including minimally invasive techniques such as lancet sampling or an automated upper arm device (TAP‐II), has the potential to replace a significant portion of hospital‐based blood sampling, thereby enhancing self‐reliance and quality of life. The objectives of this study were to assess the feasibility, reliability and preference for CEA blood collection. Methods: Baseline venous and capillary (by lancet and TAP‐II) blood samples were collected from 102 participants, including 20 CRC patients with elevated CEA levels, 60 CRC patients undergoing postoperative outpatient monitoring and 20 healthy volunteers. The second group performed capillary blood collections at home on two consecutive follow‐up appointments and subsequently sent them to the hospital. Satisfaction was assessed via patient reported outcome measures on pain, burden, ease of use and preference. Results: The Pearson's correlation test of all usable samples resulted in a linear coefficient of 0.998 (95% CI 0.997–0.998) for the TAP‐II method and 0.997 (95% CI 0.996–0.998) for the lancet method, both compared to venipuncture. Following the initial blood collection, 86% of the participants (n = 102) favoured the TAP‐II, rating it as the least painful and burdensome option. After two home‐based blood samples, the preference for the TAP‐II method persisted, with 64% of the patients endorsing its use. Conclusion: This study demonstrated the feasibility of home‐based capillary sampling of CEA. The TAP‐II blood collection is the most reliable method and is preferred by patients over venipuncture and lancet sampling. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases
- Author
-
Buisman, Florian E., van der Stok, Eric P., Galjart, Boris, Vermeulen, Peter B., Balachandran, Vinod P., Coebergh van den Braak, Robert R. J., Creasy, John M., Höppener, Diederik J., Jarnagin, William R., Kingham, T. Peter, Nierop, Pieter M. H., Sadot, Eran, Shia, Jinru, Groot Koerkamp, Bas, Grünhagen, Dirk J., D’Angelica, Michael, and Verhoef, Cornelis
- Published
- 2020
- Full Text
- View/download PDF
6. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases
- Author
-
Galjart, Boris, Nierop, Pieter M. H., van der Stok, Eric P., van den Braak, Robert R. J. Coebergh, Höppener, Diederik J., Daelemans, Sofie, Dirix, Luc Y., Verhoef, Cornelis, Vermeulen, Peter B., and Grünhagen, Dirk J.
- Published
- 2019
- Full Text
- View/download PDF
7. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
- Author
-
Nierop, Pieter MH, Höppener, Diederik J, Buisman, Florian E, van der Stok, Eric P, Galjart, Boris, Balachandran, Vinod P, Jarnagin, William R, Kingham, T Peter, Shia, Jinru, Mauer, Murielle, Nordlinger, Bernard, Julié, Catherine, Groot Koerkamp, Bas, Doukas, Michail, Vermeulen, Peter B, Grünhagen, Dirk J, D'Angelica, Michael I, and Verhoef, Cornelis
- Subjects
COLORECTAL liver metastasis ,NEOADJUVANT chemotherapy ,PROGRESSION-free survival ,HISTOPATHOLOGY ,CANCER treatment - Abstract
Histopathological growth patterns (HGPs) are a reliable, reproducible, and strong prognostic biomarker that can be assessed on haematoxylin and eosin‐stained sections of resected colorectal liver metastases (CRLM). Assessment estimates the relative fraction of the tumour–liver interface for each of the three growth patterns; the desmoplastic HGP reflects good prognosis. Whether preoperative chemotherapy affects the HGP is currently unclear. The present international multicentre study evaluates this in an original cohort of 877 consecutive patients treated in the Netherlands, an external validation cohort of 1,203 consecutive patients treated in the USA, and a post hoc analysis from the phase III randomised controlled European Organization for Research and Treatment of Cancer (EORTC) 40983 trial (n = 70). All patients underwent resection of CRLM with or without preoperative systemic chemotherapy. Trial patients were randomised between perioperative chemotherapy and resection or resection alone. HGPs were determined according to consensus guidelines and compared for preoperative treatment status. Data from three separate tumour regression grading systems were available for the trial cohort. These were correlated with HGP stratified for treatment arm. In the original cohort, the average presence of desmoplastic HGP was 43% for chemo‐naïve versus 67% for preoperatively treated patients (p < 0.001). A significant association between chemotherapy and desmoplastic HGP was found on multivariable analysis (β [95% confidence interval, CI]: 24.57 [18.28–30.87], p < 0.001). In the validation cohort, the average presence of desmoplastic HGP was 40% for chemo‐naïve versus 63% for preoperatively treated patients (p < 0.001). This association remained on multivariable analysis (β [95% CI]: 24.18 [18.70–29.66], p < 0.001). In the EORTC 40983 trial, the average desmoplastic HGP presence was 33% in the resection arm versus 61% in the chemotherapy arm (p = 0.005). Chemotherapy was independently associated with an increase in desmoplastic HGP (β [95% CI]: 23.29 [1.78–44.79], p = 0.022). All three tumour regression gradings were significantly associated with the desmoplastic HGP in the chemotherapy arm (all p < 0.04). None were associated in the resection arm (all p > 0.11). Preoperative chemotherapy induces histopathological changes that alter the HGP of CRLM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.
- Author
-
Deger, Teoman, Boers, Ruben G., de Weerd, Vanja, Angus, Lindsay, van der Put, Marjolijn M. J., Boers, Joachim B., Azmani, Z., van IJcken, Wilfred F. J., Grünhagen, Dirk J., van Dessel, Lisanne F., Lolkema, Martijn P. J. K., Verhoef, Cornelis, Sleijfer, Stefan, Martens, John W. M., Gribnau, Joost, and Wilting, Saskia M.
- Subjects
CELL-free DNA ,CIRCULATING tumor DNA ,SOMATIC mutation ,DNA sequencing ,GENETIC mutation ,COLORECTAL cancer ,METHYLATION - Abstract
Background: DNA methylation detection in liquid biopsies provides a highly promising and much needed means for real-time monitoring of disease load in advanced cancer patient care. Compared to the often-used somatic mutations, tissue- and cancer-type specific epigenetic marks affect a larger part of the cancer genome and generally have a high penetrance throughout the tumour. Here, we describe the successful application of the recently described MeD-seq assay for genome-wide DNA methylation profiling on cell-free DNA (cfDNA). The compatibility of the MeD-seq assay with different types of blood collection tubes, cfDNA input amounts, cfDNA isolation methods, and vacuum concentration of samples was evaluated using plasma from both metastatic cancer patients and healthy blood donors (HBDs). To investigate the potential value of cfDNA methylation profiling for tumour load monitoring, we profiled paired samples from 8 patients with resectable colorectal liver metastases (CRLM) before and after surgery. Results: The MeD-seq assay worked on plasma-derived cfDNA from both EDTA and CellSave blood collection tubes when at least 10 ng of cfDNA was used. From the 3 evaluated cfDNA isolation methods, both the manual QIAamp Circulating Nucleic Acid Kit (Qiagen) and the semi-automated Maxwell® RSC ccfDNA Plasma Kit (Promega) were compatible with MeD-seq analysis, whereas the QiaSymphony DSP Circulating DNA Kit (Qiagen) yielded significantly fewer reads when compared to the QIAamp kit (p < 0.001). Vacuum concentration of samples before MeD-seq analysis was possible with samples in AVE buffer (QIAamp) or water, but yielded inconsistent results for samples in EDTA-containing Maxwell buffer. Principal component analysis showed that pre-surgical samples from CRLM patients were very distinct from HBDs, whereas post-surgical samples were more similar. Several described methylation markers for colorectal cancer monitoring in liquid biopsies showed differential methylation between pre-surgical CRLM samples and HBDs in our data, supporting the validity of our approach. Results for MSC, ITGA4, GRIA4, and EYA4 were validated by quantitative methylation specific PCR. Conclusions: The MeD-seq assay provides a promising new method for cfDNA methylation profiling. Potential future applications of the assay include marker discovery specifically for liquid biopsy analysis as well as direct use as a disease load monitoring tool in advanced cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern.
- Author
-
Tabariès, Sébastien, Annis, Matthew G., Lazaris, Anthoula, Petrillo, Stephanie K., Huxham, Jennifer, Abdellatif, Amri, Palmieri, Vincent, Chabot, Jaclyn, Johnson, Radia M., Van Laere, Steven, Verhoef, Cornelis, Hachem, Yasmina, Yumeen, Sara, Meti, Nicholas, Omeroglu, Atilla, Altinel, Gulbeyaz, Gao, Zu-Hua, Yu, Alan S. L., Grünhagen, Dirk J., and Vermeulen, Peter
- Subjects
COLORECTAL cancer ,CLAUDINS ,BIOMARKERS ,XENOGRAFTS ,HISTOPATHOLOGY ,IMMUNOHISTOCHEMISTRY - Abstract
Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that Claudin-2 is functionally required for colorectal cancer liver metastasis and that Claudin-2 expression in primary colorectal cancers is associated with poor overall and liver metastasis-free survival. We have examined the role of Claudin-2, and other claudin family members, as potential prognostic biomarkers of the desmoplastic and replacement histopathological growth pattern associated with colorectal cancer liver metastases. Immunohistochemical analysis revealed higher Claudin-2 levels in replacement type metastases when compared to those with desmoplastic features. In contrast, Claudin-8 was highly expressed in desmoplastic colorectal cancer liver metastases. Similar observations were made following immunohistochemical staining of patient-derived xenografts (PDXs) that we have established, which faithfully retain the histopathology of desmoplastic or replacement type colorectal cancer liver metastases. We provide evidence that Claudin-2 status in patient-derived extracellular vesicles may serve as a relevant prognostic biomarker to predict whether colorectal cancer patients have developed replacement type liver metastases. Such a biomarker will be a valuable tool in designing optimal treatment strategies to better manage patients with colorectal cancer liver metastases. Tabariès et al. describe that claudin 2 is a promoter of colorectal cancer liver metastasis. Furthermore, high Claudin-2 expression is associated with shorter time to liver-specific recurrence and is a biomarker of replacement type CRC liver metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study.
- Author
-
Höppener, Diederik J, Galjart, Boris, Nierop, Pieter M H, Buisman, Florian E, Stok, Eric P van der, Braak, Robert R J Coebergh van den, Amerongen, Martin J van, Balachandran, Vinod P, Jarnagin, William R, Kingham, T Peter, Doukas, Michail, Shia, Jinru, Nagtegaal, Iris D, Vermeulen, Peter B, Koerkamp, Bas Groot, Grünhagen, Dirk J, Wilt, Johannes H W de, D'Angelica, Michael I, and Verhoef, Cornelis
- Subjects
HISTOPATHOLOGY ,COLORECTAL cancer ,PROGRESSION-free survival - Abstract
Background After resection of colorectal cancer liver metastases (CRLM), 2 main histopathological growth patterns can be observed: a desmoplastic and a nondesmoplastic subtype. The desmoplastic subtype has been associated with superior survival. These findings require external validation. Methods An international multicenter retrospective cohort study was conducted in patients treated surgically for CRLM at 3 tertiary hospitals in the United States and the Netherlands. Determination of histopathological growth patterns was performed on hematoxylin and eosin–stained sections of resected CRLM according to international guidelines. Patients displaying a desmoplastic histopathological phenotype (only desmoplastic growth observed) were compared with patients with a nondesmoplastic phenotype (any nondesmoplastic growth observed). Cutoff analyses on the extent of nondesmoplastic growth were performed. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier and multivariable Cox analysis. All statistical tests were 2-sided. Results In total 780 patients were eligible. A desmoplastic phenotype was observed in 19.1% and was associated with microsatellite instability (14.6% vs 3.6%, P = .01). Desmoplastic patients had superior 5-year OS (73.4%, 95% confidence interval [CI] = 64.1% to 84.0% vs 44.2%, 95% CI = 38.9% to 50.2%, P < .001) and DFS (32.0%, 95% CI = 22.9% to 44.7% vs 14.7%, 95% CI = 11.7% to 18.6%, P < .001) compared with their nondesmoplastic counterparts. A desmoplastic phenotype was associated with an adjusted hazard ratio for death of 0.36 (95% CI = 0.23 to 0.58) and 0.50 (95% CI = 0.37 to 0.66) for cancer recurrence. Prognosis was independent of KRAS and BRAF status. The cutoff analyses found no prognostic relationship between either OS or DFS and the extent of nondesmoplastic growth observed (all P > .1). Conclusions This external validation study confirms the remarkably good prognosis after surgery for CRLM in patients with a desmoplastic phenotype. The extent of nondesmoplastic growth does not affect prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Response to letter entitled: Re: Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
- Author
-
Buisman, Florian E., Grünhagen, Dirk J., Verhoef, Cornelis, and Groot Koerkamp, Bas
- Subjects
- *
PERIOPERATIVE care , *LIVER , *METASTASIS , *COLORECTAL cancer , *TUMOR markers - Published
- 2023
- Full Text
- View/download PDF
12. Multicenter Observational Study of Adhesion Formation After Open-and Laparoscopic Surgery for Colorectal Cancer.
- Author
-
Stommel, Martijn W. J., ten Broek, Richard P. G., Strik, Chema, Slooter, Gerrit D., Verhoef, Cornelis, Grünhagen, Dirk J., van Duijvendijk, Peter, Bemelmans, Marc H. A., Dulk, Marcel den, Sietses, Colin, van Heek, Tjarda N. T., van den Boezem, Peter B., de Wilt, Johannes H. W., and van Goor, Harry
- Abstract
Objective: The aim of this study was to compare adhesion formation after laparoscopic and open colorectal cancer resection. Summary of Background Data: After colorectal surgery, most patients develop adhesions, with a high burden of complications. Laparoscopy seems to reduce adhesion formation, but evidence is poor. Trials comparing open- and laparoscopic colorectal surgery have never assessed adhesion formation. Methods: Data on adhesions were gathered during resection of colorectal liver metastases. Incidence of adhesions adjacent to the original incision was compared between patients with previous laparoscopic- and open colorectal resection. Secondary outcomes were incidence of any adhesions, extent and severity of adhesions, and morbidity related to adhesions or adhesiolysis. Results: Between March 2013 and December 2015, 151 patients were included. Ninety patients (59.6%) underwent open colorectal resection and 61 patients (40.4%) received laparoscopic colorectal resection. Adhesions to the incision were present in 78.9% after open and 37.7% after laparoscopic resection (P < 0.001). The incidence of abdominal wall adhesions and of any adhesion was significantly higher after open resection; the incidence of visceral adhesions did not significantly differ. The extent of abdominal wall and visceral adhesions and the median highest Zühlke score at the incision were significantly higher after open resection. There were no differences in incidence of small bowel obstruction during the interval between the colorectal and liver operations, the incidence of serious adverse events, and length of stay after liver surgery. Conclusion: Laparoscopic colorectal cancer resection is associated with a lower incidence, extent, and severity of adhesions to parietal surfaces. Laparoscopy does not reduce the incidence of visceral adhesions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
- Author
-
Zhou, Guoying, Noordam, Lisanne, Sprengers, Dave, Doukas, Michail, Boor, Patrick P. C., van Beek, Adriaan A., Erkens, Remco, Mancham, Shanta, Grünhagen, Dirk, Menon, Anand G., Lange, Johan F., Burger, Pim J. W. A., Brandt, Alexandra, Galjart, Boris, Verhoef, Cornelis, Kwekkeboom, Jaap, and Bruno, Marco J.
- Subjects
COLON cancer ,LIVER metastasis ,T cells - Abstract
Purpose: Liver metastasis develops in >50% of patients with colorectal cancer (CRC), and is a leading cause of CRC-related mortality. We aimed to identify which inhibitory immune checkpoint pathways can be targeted to enhance functionality of intra-tumoral T-cells in mismatch repair-proficient liver metastases of colorectal cancer (LM-CRC). Methodology: Intra-tumoral expression of multiple inhibitory molecules was compared among mismatch repair-proficient LM-CRC, peritoneal metastases of colorectal cancer (PM-CRC) and primary CRC. Expression of inhibitory molecules was also analyzed on leukocytes isolated from paired resected metastatic liver tumors, tumor-free liver tissues, and blood of patients with mismatch repair-proficient LM-CRC. The effects of blocking inhibitory pathways on tumor-infiltrating T-cell responses were studied in ex vivo functional assays. Results: Mismatch repair-proficient LM-CRC showed higher expression of inhibitory receptors on intra-tumoral T-cells and contained higher proportions of CD8
+ T-cells, dendritic cells and monocytes than mismatch repair-proficient primary CRC and/or PM-CRC. Inhibitory receptors LAG3, PD-1, TIM3 and CTLA4 were higher expressed on CD8+ T-cells, CD4+ T-helper and/or regulatory T-cells in LM-CRC tumors compared with tumor-free liver and blood. Antibody blockade of LAG3 or PD-L1 increased proliferation and effector cytokine production of intra-tumoral T-cells isolated from LM-CRC in response to both polyclonal and autologous tumor-specific stimulations. Higher LAG3 expression on intra-tumoral CD8+ T-cells associated with longer progression-free survival of LM-CRC patients. Conclusion: Mismatch repair-proficient LM-CRC may be more sensitive to immune checkpoint inhibitors than mismatch repair-proficient primary CRC. Blocking LAG3 enhances tumor-infiltrating T-cell responses of mismatch repair-proficient LM-CRC, and therefore may be a new promising immunotherapeutic target for LM-CRC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.
- Author
-
Bolhuis, Karen, Bond, Marinde J.G., Van Amerongen, Martin J., Komurcu, Aysun, Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas M., Hermans, John J., De Jong, Koert P., Kazemier, Geert, Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, and Neumann, Ulf P.
- Subjects
- *
LIVER tumors , *GENETIC mutation , *CONFIDENCE intervals , *MULTIVARIATE analysis , *METASTASIS , *CANCER relapse , *COLORECTAL cancer , *CANCER patients , *EXPERIENCE , *TREATMENT effectiveness , *COMPARATIVE studies , *TRANSFERASES , *DESCRIPTIVE statistics , *REOPERATION , *LOGISTIC regression analysis , *ODDS ratio , *TUMOR markers - Abstract
Large inter-surgeon variability exists in technical anatomical resectability assessment of colorectal cancer liver-only metastases (CRLM) following induction systemic therapy. We evaluated the role of tumour biological factors in predicting resectability and (early) recurrence after surgery for initially unresectable CRLM. 482 patients with initially unresectable CRLM from the phase 3 CAIRO5 trial were selected, with two-monthly resectability assessments by a liver expert panel. If no consensus existed among panel surgeons (i.e. same vote for (un)resectability of CRLM), conclusion was based on majority. The association of tumour biological (sidedness, synchronous CRLM, carcinoembryonic antigen and RAS / BRAF V600E mutation status) and technical anatomical factors with consensus among panel surgeons, secondary resectability and early recurrence (<6 months) without curative-intent repeat local treatment was analysed by uni- and pre-specified multivariable logistic regression. After systemic treatment, 240 (50%) patients received complete local treatment of CRLM of which 75 (31%) patients experienced early recurrence without repeat local treatment. Higher number of CRLM (odds ratio 1.09 [95% confidence interval 1.03–1.15]) and age (odds ratio 1.03 [95% confidence interval 1.00–1.07]) were independently associated with early recurrence without repeat local treatment. In 138 (52%) patients, no consensus among panel surgeons was present prior to local treatment. Postoperative outcomes in patients with and without consensus were comparable. Almost a third of patients selected by an expert panel for secondary CRLM surgery following induction systemic treatment experience an early recurrence only amenable to palliative treatment. Number of CRLM and age, but no tumour biological factors are predictive, suggesting that until there are better biomarkers; resectability assessment remains primarily a technical anatomical decision. • Role of tumour biological factors in resectability assessment of colorectal cancer liver-only metastases was evaluated. • 31% of locally treated patients had early recurrence without repeat local treatment. • Number of colorectal cancer liver-only metastases and age are predictive for early recurrence without repeat local treatment. • Resectability assessment remains primarily a technical anatomical decision. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Follow-up strategy and survival for five common cancers: A meta-analysis.
- Author
-
Galjart, Boris, Höppener, Diederik J., Aerts, Joachim G.J.V., Bangma, Christiaan H., Verhoef, Cornelis, and Grünhagen, Dirk J.
- Subjects
- *
TUMOR treatment , *PATIENT aftercare , *META-analysis , *CONFIDENCE intervals , *SYSTEMATIC reviews , *CANCER relapse , *LUNG tumors , *COLORECTAL cancer , *GASTROINTESTINAL tumors , *TUMORS , *BREAST tumors , *PROSTATE tumors - Abstract
This meta-analysis aimed to evaluate the effectiveness of intensive follow-up after curative intent treatment for five common solid tumours, in terms of survival and treatment of recurrences. A systematic literature search was conducted, identifying comparative studies on follow-up for colorectal, lung, breast, upper gastro-intestinal and prostate cancer. Outcomes of interest were overall survival (OS), cancer specific survival (CSS), and treatment of recurrences. Random effects meta-analyses were conducted, with particular focus on studies at low risk of bias. Fourteen out of 63 studies were considered to be at low risk of bias (8 colorectal, 4 breast, 0 lung, 1 upper gastro-intestinal, 1 prostate). These studies showed no significant impact of intensive follow-up on OS (hazard ratio, 95% confidence interval) for colorectal (0.99; 0.92–1.06), breast 1.06 (0.92–1.23), upper gastro-intestinal (0.78; 0.51–1.19) and prostate cancer (1.00; 0.86–1.16). No impact on CSS (hazard ratio, 95% confidence interval) was found for colorectal cancer (0.94; 0.77–1.16). CSS was not reported for other cancer types. Intensive follow-up increased the rate of curative treatment (relative risk; 95% confidence interval) for colorectal cancer recurrences (1.30; 1.05–1.61), but not for upper gastro-intestinal cancer recurrences (0.92; 0.47–1.81). For the other cancer types, no data on treatment of recurrences was available in low risk studies. For colorectal and breast cancer, high quality studies do not suggest an impact of intensive follow-up strategies on survival. Colorectal cancer recurrences are more often treated locally after intensive follow-up. For other cancer types evaluated, limited high quality research on follow-up is available. • Intensive follow-up after surgery for colorectal and breast cancer has little impact on survival. • Colorectal cancer recurrences are more often treated locally after intensive follow-up. • High quality research on follow-up for other cancers is scarce. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
- Author
-
Buisman, Florian E., Giardiello, Daniele, Kemeny, Nancy E., Steyerberg, Ewout W., Höppener, Diederik J., Galjart, Boris, Nierop, Pieter M.H., Balachandran, Vinod P., Cercek, Andrea, Drebin, Jeffrey A., Gönen, Mithat, Jarnagin, William R., Kingham, T.P., Vermeulen, Peter B., Wei, Alice C., Grünhagen, Dirk J., Verhoef, Cornelis, D'Angelica, Micheal I., and Koerkamp, Bas Groot
- Subjects
- *
BIOMARKERS , *PERIOPERATIVE care , *LIVER tumors , *METASTASIS , *COLORECTAL cancer , *CANCER patients , *DESCRIPTIVE statistics , *PREDICTION models , *DATA analysis software - Abstract
The aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection of colorectal liver metastasis (CRLM) based on patient, tumour and treatment characteristics. Consecutive patients after complete resection of CRLM were included from two centres (1992–2019). A prediction model providing 10-year OS probabilities was developed using Cox regression analysis, including KRAS, BRAF and histopathological growth patterns. Discrimination and calibration were assessed using cross-validation. A web-based calculator was built to predict individual 10-year OS probabilities. A total of 4112 patients were included. The estimated 10-year OS was 30% (95% CI 29–32). Fifteen patient, tumour and treatment characteristics were independent prognostic factors for 10-year OS; age, gender, location and nodal status of the primary tumour, disease-free interval, number and diameter of CRLM, preoperative CEA, resection margin, extrahepatic disease, KRAS and BRAF mutation status, histopathological growth patterns, perioperative systemic chemotherapy and hepatic arterial infusion pump chemotherapy. The discrimination at 10-years was 0.73 for both centres. A simplified risk score identified four risk groups with a 10-year OS of 57%, 38%, 24%, and 12%. Ten-year OS after resection of CRLM is best predicted with a model including 15 patient, tumour, and treatment characteristics. The web-based calculator can be used to inform patients. This model serves as a benchmark to determine the prognostic value of novel biomarkers. • A prediction model for a 10-year OS after colorectal liver metastasis resection was developed. • Fifteen characteristics were independent factors (discrimination: 0.73). • A risk score identified four groups with a 10-year OS of 57%, 38%, 24% and 12%. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Can medical imaging identify the histopathological growth patterns of liver metastases?
- Author
-
Latacz, Emily, van Dam, Pieter-Jan, Vanhove, Christian, Llado, Laura, Descamps, Benedicte, Ruiz, Núria, Joye, Ines, Grünhagen, Dirk, Van Laere, Steven, Dirix, Piet, Mollevi, David G., Verhoef, Cornelis, Dirix, Luc, and Vermeulen, Peter
- Subjects
- *
LIVER metastasis , *METASTATIC breast cancer , *LIVER surgery , *DIAGNOSTIC imaging , *COLORECTAL cancer , *LIVER cancer - Abstract
The histopathological growth patterns (HGPs) of liver metastases of colorectal cancer and of several other tumor types predict outcome of patients in multiple studies. The HGPs of liver metastases have a prognostic but also a predictive value with one of the growth patterns, the replacement growth pattern, related to resistance to systemic treatment. Given that the HGP can only be assessed in a reliable manner when a surgical resection of the metastasis has been performed, this biomarker cannot be exploited to the full. For example, HGPs can at this moment, not be used to decide whether patients with liver metastatic breast or colorectal cancer will benefit or not from locoregional treatment, such as surgery or radiotherapy, and from peri-operative systemic treatment. In this review we highlight studies that suggest that the HGPs of liver metastases can be identified by medical imaging. Although still to be confirmed by a prospective multicenter approach, some studies indeed achieve a high accuracy in predicting the HGPs by applying radiomic algorithms on CT- or MR-images of liver metastases. This is an important step towards a treatment planning of patients with liver metastatic cancer that takes into account the biology and the progression kinetics of the metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.